1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Asia Pacific Biodefense Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Asia Pacific Biodefense Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Asia Pacific Biodefense Market Regional Analysis
6.2 Asia Pacific Biodefense Market Revenue 2017-2027 (US$ Million)
6.3 Asia Pacific Biodefense Market Forecast Analysis
7. Asia Pacific Biodefense Market Analysis – by Product
7.1 Anthrax
- 7.1.1 Overview
- 7.1.2 Anthrax: Asia Pacific Biodefense Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.2 Small pox
- 7.2.1 Overview
- 7.2.2 Small pox: Asia Pacific Biodefense Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.3 Botulism
- 7.3.1 Overview
- 7.3.2 Botulism: Asia Pacific Biodefense Market – Revenue and Forecast, 2017-2027 (US$ Million)
7.4 Radiation/Nuclear
- 7.4.1 Overview
- 7.4.2 Radiation/Nuclear: Asia Pacific Biodefense Market – Revenue and Forecast, 2017-2027 (US$ Million)
8. Asia Pacific Biodefense Market – Asia-Pacific Analysis
8.1 Overview
8.2 Asia-Pacific
- 8.2.1 Asia Pacific Biodefense Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 8.2.1.1 Asia Pacific Biodefense Market – Revenue and
Forecast Analysis – by Country
- 8.2.1.1 China:
Asia Pacific Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
- 8.2.1.1.1 China: Asia Pacific Biodefense Market Breakdown, by Product
- 8.2.1.2 India:
Asia Pacific Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
- 8.2.1.2.1 India: Asia Pacific Biodefense Market Breakdown, by Product
- 8.2.1.3 Japan:
Asia Pacific Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
- 8.2.1.3.1 Japan: Asia Pacific Biodefense Market Breakdown, by Product
- 8.2.1.4 Australia:
Asia Pacific Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
- 8.2.1.4.1 Australia: Asia Pacific Biodefense Market Breakdown, by Product
- 8.2.1.5 Rest of Asia-Pacific :
Asia Pacific Biodefense Market – Revenue and Forecast to 2027 (US$ Million)
- 8.2.1.5.1 Rest of Asia-Pacific : Asia Pacific Biodefense Market Breakdown, by Product
9. Competitive Landscape
9.1 Heat Map Analysis
9.2 Company Positioning and Concentration
10. Industry Landscape
10.1 Overview
10.2 Market Initiative
10.3 Partnerships and Collaborations
10.4 Other Developments
11. Company Profiles
11.1 Bavarian Nordic
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Alnylam Pharmaceuticals, Inc.
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 SIGA Technologies
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Emergent BioSolutions Inc.
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 Cleveland Bio Labs
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Dynavax Technologies
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Elusys Therapeutics, Inc.
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Soligenix
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Altimmune
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments
11.10 Pluristem Therapeutics
- 11.10.1 Key Facts
- 11.10.2 Business Description
- 11.10.3 Products and Services
- 11.10.4 Financial Overview
- 11.10.5 SWOT Analysis
- 11.10.6 Key Developments
12. Appendix
12.1 About Business Market Insights
12.2 List of Abbreviations